AstraZeneca’s Promise To Investors: 10 New Drugs By 2020
This article was originally published in The Pink Sheet Daily
CEO Pascal Soriot said the big pharma is on track to return to growth faster than anticipated, with 2017 revenues expected to be in line with 2013. A key driver of growth will be new drugs, many of which have been gained through deal-making and acquisitions.
You may also be interested in...
Ranbaxy’s ability to launch generic versions of AstraZeneca’s blockbuster Nexium in the U.S. on May 27 was uncertain already. Sun’s proposed $4 billion acquisition of Ranbaxy could further distract the troubled Indian generics firm from achieving that goal.
AstraZeneca’s SGLT-2 inhibitor Farxiga (dapagliflozin) finally clears FDA, and without a black box warning on bladder cancer risk – allowing the drug to compete with J&J’s first-to-market Invokana.
AstraZeneca will acquire all of Bristol’s interests in their current diabetes alliance. In doing so, AZ believes its geographic reach and scale in assets and capabilities position it to succeed, while Bristol retreats from diabetes to focus on specialty biologics, notably its PD-1 franchise.